Akero Therapeutics Statistics Share Statistics Akero Therapeutics has 79.99M
shares outstanding. The number of shares has increased by 14.6%
in one year.
Shares Outstanding 79.99M Shares Change (YoY) 14.6% Shares Change (QoQ) 0.34% Owned by Institutions (%) 99.99% Shares Floating 67.78M Failed to Deliver (FTD) Shares 47 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 9.09M, so 11.37% of the outstanding
shares have been sold short.
Short Interest 9.09M Short % of Shares Out 11.37% Short % of Float 11.69% Short Ratio (days to cover) 7.71
Valuation Ratios The PE ratio is -7.41 and the forward
PE ratio is -11.
Akero Therapeutics's PEG ratio is
-0.25.
PE Ratio -7.41 Forward PE -11 PS Ratio 0 Forward PS 1143 PB Ratio 2.49 P/FCF Ratio -8.12 PEG Ratio -0.25
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Akero Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 19.38,
with a Debt / Equity ratio of 0.05.
Current Ratio 19.38 Quick Ratio 19.38 Debt / Equity 0.05 Debt / EBITDA -0.13 Debt / FCF -0.16 Interest Coverage -61.14
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.65M Employee Count 69 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 63.24% in the
last 52 weeks. The beta is -0.29, so Akero Therapeutics's
price volatility has been lower than the market average.
Beta -0.29 52-Week Price Change 63.24% 50-Day Moving Average 47.13 200-Day Moving Average 44.57 Relative Strength Index (RSI) 48.59 Average Volume (20 Days) 1,157,682
Income Statement
Revenue n/a Gross Profit -18K Operating Income -285.42M Net Income -252.06M EBITDA -285.42M EBIT -256.73M Earnings Per Share (EPS) -3.75
Full Income Statement Balance Sheet The company has 340.24M in cash and 36.12M in
debt, giving a net cash position of 304.12M.
Cash & Cash Equivalents 340.24M Total Debt 36.12M Net Cash 304.12M Retained Earnings -826.16M Total Assets 1.11B Working Capital 704.2M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -230.11M
and capital expenditures -999K, giving a free cash flow of -230.11M.
Operating Cash Flow -230.11M Capital Expenditures -999K Free Cash Flow -230.11M FCF Per Share -3.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
